Introduction: The reported ROM within TBSRTC categories varies widely and depends on several factors in the clinical care pathway for thyroid nodules, including sonographic risk stratification, cytology expertise, selection criteria for surgical resection, and definitions of malignancy used. Methods: We present 5,867 consecutive thyroid FNAC and corresponding surgical pathology in the context of a comprehensive, single-payer health care system with centralized cytology and surgical pathology services for over 1.5 million inhabitants. Results: We report higher usage of ND and AUS/FLUS categories than the literature (19% vs. <10% and 15% vs. <10%, respectively). Our surgical resection rate for malignant cytology is substantially higher than the literature (94% vs. 50%, respectively). The ROM by the TBSRTC category in our cohort was similar to the literature. The overall diagnostic accuracy of thyroid FNAC was 92%, which is similar to other studies. Inclusion of incidental PMC as histologically malignant raised the ROM in the ND, benign, and AUS/FLUS categories. Discussion: The diagnostic performance of thyroid FNAC in our study is similar to the reported literature. Differences in TBSRTC category usage likely arise from cytologist variability and expertise. Our higher surgical resection rate in the malignant cytology category reflects the greater capture of surgical follow-up within our healthcare region with centralized pathology and a single EMR system. Keeping in mind the method of calculation of ROM, the malignancy rate by TBSRTC is similar to previous reports.

1.
Haugen
BR
,
Alexander
EK
,
Bible
KC
,
Doherty
G
,
Mandel
SJ
,
Nikiforov
Y
,
2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer
.
Thyroid
.
2015
;
26
(
1
):
1
133
.
2.
Cobin
RH
,
Gharib
H
,
Bergman
D
,
Clark
O
,
Cooper
DS
,
Daniels
GH
,
American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: 2016 update
.
Endocr Pract
.
2016
;
22
:
622
39
.
3.
Tessler
FN
,
Middleton
WD
,
Grant
EG
,
Hoang
JK
,
Berland
LL
,
Teefey
SA
,
ACR Thyroid Imaging, Reporting and Data System (TI-RADS): white paper of the ACR TI-RADS Committee
.
J Am Coll Radiol
.
2017
;
14
:
587
95
.
4.
Cibas
ES
,
Ali
SZ
.
The 2017 Bethesda system for reporting thyroid cytopathology
.
Thyroid
.
2017
;
27
(
11
):
1341
6
. .
5.
Bongiovanni
M
,
Spitale
A
,
Faquin
W
,
Mazzucchelli
L
,
Baloch
Z
.
The Bethesda system for reporting thyroid cytopathology: a meta analysis
.
Acta Cytol
.
2012
;
56
:
333
9
.
6.
Lewis
CM
,
Chang
KP
,
Pitman
M
,
Faquin
WC
,
Randolph
GW
.
Thyroid fine-needle aspiration biopsy: variability in reporting
.
Thyroid
.
2009
;
19
(
7
):
717
23
. .
7.
Iskandar
M
,
Bonomo
G
,
Avadhani
V
,
Persky
M
,
Lucido
M
,
Wang
B
,
Evidence for overestimation of the prevalence of malignancy in indeterminate thyroid nodules classified as Bethesda category III
.
Surgery
.
2015
;
157
(
3
):
510
7
.
8.
Tee
YY
,
Lowe
AJ
,
Brand
CA
,
Judson
RT
.
Fine-needle aspiration may miss a third of all malignancy in palpable thyroid nodules: a comprehensive literature review
.
Ann Surg
.
2007
;
246
(
5)
:
714
20
. .
9.
Symonds
CJ
,
Seal
P
,
Ghaznavi
S
,
Cheung
WY
,
Paschke
R
.
Thyroid nodule ultrasound reports in routine clinical practice provide insufficient information to estimate risk of malignancy
.
Endocrine
.
2018
;
61
(
2
):
303
7
. .
10.
Renshaw
AA
.
Accuracy of thyroid fine-needle aspiration using receiver operator characteristic curves
.
Am J Clin Pathol
.
2001
;
116
(
4
):
477
82
. .
11.
Yang
J
,
Schnadig
V
,
Logrono
R
,
Wasserman
PG
.
Fine-needle aspiration of thyroid nodules: a study of 4,703 patients with histologic and clinical correlations
.
Cancer
.
2007
;
111
:
306
15
. .
12.
Wang
CC
,
Friedman
L
,
Kennedy
GC
,
Wang
H
,
Kebebew
E
,
Steward
DL
,
A large multicentre correlation study of thyroid nodule cytopathology and histopathology
.
Thyroid
.
2011
;
21
(
3
):
243
51
.
13.
Eszlinger
M
,
Ullmann
M
,
Ruschenburg
I
,
Bohme
K
,
Gorke
R
,
Franzius
C
,
Low malignancy rates in fine-needle aspiration cytologies in a primary care setting in Germany
.
Thyroid
.
2017
;
27
(
11
):
1385
92
.
14.
Guidelines of the Papanicolaou Society of Cytopathology for the examination of fine-needle aspiration specimens from thyroid nodules. The Papanicolaou Society of Cytopathology Task Force on Standards of Practice
.
Mod Pathol
.
1996
;
9
(
1
):
710
5
.
15.
Straccia
P
,
Rossi
E
,
Bizzarro
T
,
Brunelli
C
,
Cianfrini
F
,
Damiani
D
,
A meta-analytic review of the Bethesda system for reporting thyroid cytopathology: has the rate of malignancy in indeterminate lesions been underestimated?
Cancer Cytopathol
.
2015
;
123
:
713
22
.
16.
Krane
JF
,
VanderLaan
PA
,
Faquin
WC
,
Renshaw
AA
.
The atypia of undetermined significance/follicular lesion of undetermined significance: malignant ratio–a proposed performance measure for reporting in the Bethesda System for thyroid cytopathology
.
Cancer Cytopathol
.
2012
;
120
:
111
6
.
17.
Fazeli
R
,
Schneider
EB
,
Ali
SZ
,
Zeiger
MA
,
Olson
MT
.
Diagnostic frequency ratios are insufficient to measure laboratory precision with the Bethesda System for reporting thyroid cytopathology
.
Acta Cytol
.
2015
;
59
:
225
32
. .
18.
Gunes
P
,
Canberk
S
,
Onenerk
M
,
Erkan
M
,
Gursan
N
,
Kilinc
E
,
A different perspective on evaluating the malignancy rate of the non-diagnostic category of the Bethesda system for reporting thyroid cytopathology: a single institute experience and review of the literature
.
PLoS One
.
2016
;
11
(
9
):
e0162745
.
19.
Le
AR
,
Thompson
GW
,
Hoyt
BJ
.
Thyroid fine-needle aspiration biopsy: an evaluation of its utility in a community setting
.
J Otolaryngol Head Neck Surg
.
2015
;
44
(
12
)
12
6
. .
20.
Jo
VY
,
Stelow
EB
,
Dustin
SM
,
Hanley
KZ
.
Malignancy risk for fine-needle aspiration of thyroid lesions according to The Bethesda System for reporting thyroid cytopathology
.
Am J Clin Pathol
.
2010
;
134
:
450
6
. .
21.
Sarkis
LM
,
Norlen
O
,
Aniss
A
,
Watson
N
,
Delbridge
LW
,
Sidhu
SB
,
The Australian experience with the Bethesda classification system for thyroid fine needle aspiration biopsies
.
Pathology
.
2014
;
46
(
7
):
592
5
. .
22.
Lew
JI
,
Snyder
RA
,
Sanchez
YM
,
Solorzano
CC
.
Fine needle aspiration of the thyroid: correlation with final histopathology in a surgical series of 797 patients
.
J Am Coll Surg
.
2011
;
213
(
1
):
188
5
. .
23.
Theoharis
CG
,
Schofield
KM
,
Hammers
L
,
Udelsman
R
,
Chhieng
DC
.
The Bethesda thyroid fine-needle classification system: year 1 at an academic institution
.
Thyroid
.
2009
;
19
:
1215
23
.
24.
Wu
HH
,
Rose
C
,
Elsheikh
TM
.
The Bethesda System for reporting thyroid cytopathoogy: an experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy
.
Diagn Cytopathol
.
2012
;
40
:
399
403
.
25.
Mufti
ST
,
Molah
R
.
The Bethesda System for reporting thyroid cytopathology: a five year retrospective review of one center experience
.
Int J Health Sci
.
2012
;
6
:
159
73
.
26.
Mondal
SK
,
Sinha
S
,
Basak
B
,
Roy
DN
,
Sinha
SK
.
The Bethesda System for reporting thyroid fine needle aspirates: a cytologic study with histologic follow up
.
J Cytol
.
2013
;
30
:
94
9
.
27.
Richmond
BK
,
Judhan
R
,
Chong
B
,
Ubert
A
,
Aburahma
Z
,
Mangano
W
,
False-negative results with the Bethesda System for reporting thyroid cytopathology: predictors of malignancy in thyroid nodules classified as benign by cytopathologic evaluation
.
Am Surg
.
2014
;
80
(
8
):
811
6
.
28.
Piana
S
,
Frasoldati
A
,
Ferrari
M
,
Valcavi
R
,
Froio
E
,
Barbieri
V
,
Is a five-category reporting scheme for thyroid fine needle aspiration cytology accurate? Experience of over 18,000 FNAs reported at the same institution 1998–2007
.
Cytopathology
.
2011
;
22
:
164
73
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.